Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Debt Ratio (2016 - 2023)

Endonovo Therapeutics has reported Debt Ratio over the past 11 years, most recently at 7.24 for Q3 2023.

  • Quarterly results put Debt Ratio at 7.24 for Q3 2023, up 100.57% from a year ago — trailing twelve months through Sep 2023 was 7.24 (up 100.57% YoY), and the annual figure for FY2022 was 13.55, up 690.01%.
  • Debt Ratio for Q3 2023 was 7.24 at Endonovo Therapeutics, up from 5.82 in the prior quarter.
  • Over the last five years, Debt Ratio for ENDV hit a ceiling of 13.55 in Q4 2022 and a floor of 1.03 in Q1 2019.
  • Median Debt Ratio over the past 5 years was 2.6 (2021), compared with a mean of 3.52.
  • Biggest five-year swings in Debt Ratio: tumbled 50.2% in 2020 and later surged 690.01% in 2022.
  • Endonovo Therapeutics' Debt Ratio stood at 3.24 in 2019, then tumbled by 50.2% to 1.61 in 2020, then rose by 6.39% to 1.71 in 2021, then surged by 690.01% to 13.55 in 2022, then tumbled by 46.59% to 7.24 in 2023.
  • The last three reported values for Debt Ratio were 7.24 (Q3 2023), 5.82 (Q2 2023), and 7.78 (Q1 2023) per Business Quant data.